Cara Therapeutics Inc., a Stamford-headquartered commercial-stage biopharmaceutical company focused on creating a new treatment paradigm to improve the lives of patients suffering from pruritus, has entered into a royalty interest purchase and sale agreement with HealthCare Royalty (HCRx), also based in Stamford.